Toggle Main Menu Toggle Search

Open Access padlockePrints

Hypercoagulability in cirrhosis: causes and consequences

Lookup NU author(s): Professor Quentin Anstee

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Decreased levels of most coagulation factors and thrombocytopenia are the main haemostatic abnormalities of cirrhosis. As a consequence, this condition was, until recently, considered as the prototype acquired coagulopathy responsible for bleeding. However, recent evidence suggests that it should, rather, be regarded as a condition associated with normal or even increased thrombin generation. The bleeding events that occur in these patients should, therefore, be explained by the superimposed conditions that frequently occur in this setting. Due to elevated levels of factor VIII (procoagulant driver) in combination with decreased protein C (anticoagulant driver), which are typically found in patients with cirrhosis, a procoagulant imbalance, defined as a partial resistance to the in vitro anticoagulant action of thrombomodulin, can be demonstrated. Whether this in vitro hypercoagulability is truly representative of what occurs in vivo remains to be established. However, the hypothesis that it may have clinical consequences is attractive and deserves attention. The possible consequences that we discuss herein include whether (i) cirrhosis is a condition associated with increased risk of venous thromboembolism or portal vein thrombosis; (ii) the hypercoagulability associated with cirrhosis has any other role outside coagulation (i. e. progression of liver fibrosis); and (iii) anticoagulation should be used in cirrhosis. Although apparently provocative, considering anticoagulation as a therapeutic option in patients with cirrhosis is now supported by a rationale of increasing strength. There may be subgroups of patients who benefit from anticoagulation to treat or prevent thrombosis and to slow hepatic fibrosis. Clinical studies are warranted to explore these therapeutic options.


Publication metadata

Author(s): Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC

Publication type: Review

Publication status: Published

Journal: Journal of Thrombosis and Haemostasis

Year: 2011

Volume: 9

Issue: 9

Pages: 1713-1723

Print publication date: 02/09/2011

ISSN (print): 1538-7933

ISSN (electronic): 1538-7836

Publisher: WILEY-BLACKWELL

URL: http://dx.doi.org/10.1111/j.1538-7836.2011.04429.x

DOI: 10.1111/j.1538-7836.2011.04429.x


Actions

Find at Newcastle University icon    Link to this publication


Share